Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00015964 · ClinicalTrials.gov registry record · Phase 2
ZD 1839 in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck
A Phase 2 study, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 2
- Development phase
- 51
- Enrollment target
NCT00015964 is a Phase 2 study that has completed, run by University of Chicago. The registered enrollment target is 51 participants.
The verdict
NCT00015964, a Phase 2 study, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 51 participants
- Enrollment target
Study Summary
RATIONALE: Biological therapies such as ZD 1839 may interfere with the growth of tumor cells and slow the growth of head and neck cancer. PURPOSE: Phase II trial to study the effectiveness of ZD1839 in treating patients who have metastatic or recurrent cancer of the head and neck.
Interventions
- DRUG ZD1839
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2001-03 |
| Est. Completion | 2005-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00015964
The ClinicalTrials.gov registry entry for NCT00015964 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ZD1839 is the first listed.
NCT00015964 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00015964 about?
NCT00015964 is a clinical study titled "ZD 1839 in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck". RATIONALE: Biological therapies such as ZD 1839 may interfere with the growth of tumor cells and slow the growth of head and neck cancer. PURPOSE: Phase II trial to study the effectiveness of ZD1839 in treating patients who have metastatic or recurrent cancer of the head and neck.
What is the current status of trial NCT00015964?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 51 participants. The study started on 2001-03. Estimated completion is 2005-07.
What interventions are being tested in trial NCT00015964?
The interventions under investigation include: ZD1839 (DRUG).
Who is sponsoring clinical trial NCT00015964?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.